期刊文献+

比较实时荧光PCR法与Sanger测序法检测甲状腺乳头状癌BRAF基因突变 被引量:3

Comparison of real-time PCR method with Sanger sequencing for detection of BRAF mutation in papillary thyroid carcinoma
下载PDF
导出
摘要 目的分析实时荧光PCR(real-time PCR)法与Sanger测序法检测甲状腺乳头状癌患者BRAF V600E基因突变的阳性率及符合率。方法收集312例甲状腺乳头状癌手术切除标本,分别采用real-time PCR法和Sanger测序法检测甲状腺乳头状癌中BRAF V600E基因突变情况。结果 312例甲状腺乳头状癌标本real-time PCR法和Sanger测序法检出BRAF基因突变的阳性率分别为65.4%(204/312)、63.8%(199/312)。BRAF基因突变与患者性别无关,与患者年龄相关;两种方法检测结果总符合率为98.4%。结论 real-time PCR法适用于BRAF基因突变的检测。 Purpose To investigate the positive rate and concordance rate of BRAF mutation in papillary thyroid carcinoma detected by real-time PCR method and Sanger sequencing. Methods 312 papillary thyroid carcinomas patients were enrolled in this study. Real-time PCR method and Sanger sequencing were performed to detect BRAF gene mutations. The frequency of BRAF mutation and the concordance of two methods were analyzed. Results BRAF mutation was detected in 65. 4% (204/312) and 63. 8% (199/312) of 312 papillary thyroid carcinoma samples by using real-time PCR method and Sanger sequencing, respectively. There was no significant correlation between BRAF gene mutations and patients’ gender. There was significant correlation between BRAF gene mutations and patients’ age. The overall concordance between real-time PCR method and Sanger sequencing for BRAF mutation detection was 98. 4%. Conclusion Real-time PCR method provides an effective method in BRAF gene mutation detection.
出处 《临床与实验病理学杂志》 CAS CSCD 北大核心 2015年第7期756-758,共3页 Chinese Journal of Clinical and Experimental Pathology
关键词 甲状腺肿瘤 乳头状癌 BRAF基因突变 实时荧光PCR Sanger测序 thyroid neoplasm papillary carcinoma BRAF gene mutation real-time PCR Sanger sequencing
  • 相关文献

参考文献14

  • 1Rajagopalan H, Bardelli A, Lengauer C, et al. Tumorigenesis : RAF/RAS oncogenes and mismatch-repair status [ J ]. Nature, 2002,418 (6901) :934.
  • 2Davies H, Bignell G R, Cox C, et al. Mutations of the BRAF gene in human cancer [ J ]. Nature, 2002,417 (6892) :949 - 54.
  • 3Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma[ J]. J Natl Cancer Inst, 2003,95 (8) :625 - 7.
  • 4Xing M, Westra W H, Tufano R P, et al. BRAF mutation pre- dicts a poorer clinical prognosis for papillary thyroid cancer[ J]. J Clin Endocrinol Metab, 2005,90(12) :6373 -9.
  • 5Pelizzo M R, Dobrinja C, Casal lde E, et al. The role of BRAF (V600E) mutation as poor prognostic factor for the outcome of pa- tients with intrathyroid papillary thyroid carcinoma [J]. Biomed Pharmacother, 20f 4,68 ( 4 ) :413 - 7.
  • 6Daliri M, Abhaszadegan M R, Bahar M M, et al. The role of BRAF V600E mutation as a potential marker for prognostic stratifi- cation of papillary thyroid carcinoma: a long-term follow-up study [J]. Endocr Res, 2014,39(4) :189 -93.
  • 7He G, Zhao B, Zhang X, Gong R. Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma [ J ]. Oncol Lett, 2014,7(2) :439 -43.
  • 8Xing M. BRAF mutation in thyroid cancer [ J ]. Endocr Relat Cancer, 2005,12(2) :245 -62.
  • 9Park A Y, Son E J, Kim J A, et al. Associations of the BRAF (V60OE) mutation with sonographic features and clinicopathologic characteristics in a large population with conventional papillary thyroid carcinoma[J]. PLoS One, 2014,9 (10) : e110868.
  • 10Ahn H Y, Chung Y J, Kim B S, et al. Clinical significance of the BRAF V600E mutation in muhifocal papillary thyroid carcinoma in Korea[J]. Surgery, 2014,155(4) :689 -95.

二级参考文献17

  • 1Siegel R, Naishadham D, Jemal A. Cancer statistics for Hispanics/Latinos, 2012[J]. CA Cancer J Clin, 2012,62(5):283-98.
  • 2Pellegriti G, Frasca F, Regalbuto C, et al. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors[J]. J Cancer Epidemiol, 2013,2013:965212.
  • 3Guan H, Ji M, Xing M, et al. Association of high iodine intake with the T1779A BRAF mutation in papillary thyroid cancer[J]. J Clin Endocrinol Metab, 2009,94(5):1612-7.
  • 4Kim T H, Park Y J, Lim J A, et al. The association of the BRAF(V600E)mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer:a meta-analysis[J]. Cancer, 2012,118(7):1764-73.
  • 5Edge S B, Byrd D R, Carducci M A, et al. AJCC Cancer Staging Manual[M]. 7th ed. New York: Springer, 2009:87-96.
  • 6Shao J, Teraishi F, Katsuda K, et al. p53 inhibits adriamycin-induced down-regulation of cyclin D1 expression in human cancer cells[J]. Biochem Biophys Res Commun, 2002,290(3):1101-7.
  • 7Frasca F, Nucera C, Pellegriti C, et al. BRAF(V600E)mutateon and the biology of papillary thyroid cancer[J]. Endoer Rlat Cancer, 2008,15(1):191-205.
  • 8Nikiforov Y E, Nikiforova M N. Molecular genetics and diagnosis of thyoid cancer[J]. Nat Rev Endocrinol, 2011,7(10):569-80.
  • 9Rodolico V, Cabibi D, Pizzolanti G, et al. BRAF V600E mutateon and p27 kip1 expression in papillary carcinomas of the thyroid ≤1cm and their paired lymph node metastases[J]. Cancer, 2007,110(6):1216-8.
  • 10Xing M. BRAF mutateon in thyroid cancer[J]. Endecr Relat Cancer, 2005,12(2):245-62.

共引文献23

同被引文献18

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部